Rating Change #7
has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Highlights from the ratings report include:
- PHARMATHENE INC has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, PHARMATHENE INC reported poor results of -$0.10 versus -$0.07 in the prior year. For the next year, the market is expecting a contraction of 240.0% in earnings (-$0.34 versus -$0.10).
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 269.6% when compared to the same quarter one year ago, falling from $0.75 million to -$1.27 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Biotechnology industry and the overall market, PHARMATHENE INC's return on equity significantly trails that of both the industry average and the S&P 500.
- PIP, with its decline in revenue, underperformed when compared the industry average of 6.8%. Since the same quarter one year prior, revenues slightly dropped by 3.6%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
- Looking at where the stock is today compared to one year ago, we find that it is higher, and it has outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Turning our attention to the future direction of the stock, we do not believe this stock offers ample reward opportunity to compensate for the risks, despite the fact that it rose over the past year.
PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical threats in the United States. PharmAthene has a market cap of $95.8 million and is part of the health care sector and drugs industry. Shares are up 76.8% year to date as of the close of trading on Thursday.
You can view the full
PharmAthene Ratings Report
or get investment ideas from our
investment research center